Compare KFY & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KFY | CORT |
|---|---|---|
| Founded | 1969 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.7B |
| IPO Year | 1999 | N/A |
| Metric | KFY | CORT |
|---|---|---|
| Price | $60.49 | $38.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $78.00 | ★ $114.20 |
| AVG Volume (30 Days) | 459.8K | ★ 2.0M |
| Earning Date | 03-10-2026 | 02-18-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | ★ 5.12 | N/A |
| EPS | ★ 4.91 | 0.87 |
| Revenue | ★ $2,811,089,000.00 | $741,172,000.00 |
| Revenue This Year | $5.60 | $23.09 |
| Revenue Next Year | $4.16 | $29.62 |
| P/E Ratio | ★ $12.71 | $46.75 |
| Revenue Growth | 3.78 | ★ 17.92 |
| 52 Week Low | $59.23 | $32.99 |
| 52 Week High | $78.50 | $117.33 |
| Indicator | KFY | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 32.64 | 36.31 |
| Support Level | $66.53 | $38.10 |
| Resistance Level | $68.31 | $41.92 |
| Average True Range (ATR) | 2.25 | 2.14 |
| MACD | -0.71 | 1.03 |
| Stochastic Oscillator | 3.66 | 16.96 |
Korn Ferry is a consulting firm that powers performance. The Company helps unlock the potential in people and unleash transformation across organizations synchronizing, operations, and talent to accelerate performance, fuel growth, and inspire a legacy of change. The company's segment includes Consulting, Digital, Executive Search North America, Executive Search EMEA, Executive Search APAC, Executive Search Latin America, Professional Search & Interim and RPO. The company generates the majority of its revenue from the Executive Search segment and Consulting segment. The Executive search segment helps organizations recruit board-level, chief executive, and other C-suite/senior executive and general management talent to deliver lasting impact.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.